Phadia
Phadia, a leading name in the field of allergy and autoimmune diagnostics, is headquartered in the Czech Republic (CZ). Founded in 2000, the company has established itself as a key player in the global diagnostics industry, with a strong presence in Europe, North America, and Asia. Phadia is renowned for its innovative products, including the ImmunoCAP system, which offers precise and reliable testing for allergies and autoimmune diseases. This unique technology sets Phadia apart, enabling healthcare professionals to deliver accurate diagnoses and tailored treatment plans. With a commitment to advancing diagnostic solutions, Phadia has achieved significant milestones, including numerous certifications and partnerships that enhance its market position. The company continues to lead the way in improving patient outcomes through cutting-edge diagnostic tools and a focus on research and development.
DitchCarbon Score
How does Phadia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Phadia's score of 80 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Phadia, headquartered in the Czech Republic (CZ), currently does not report specific carbon emissions data, as no emissions figures are available. The company is a current subsidiary of Thermo Fisher Scientific Inc., which influences its climate commitments and initiatives. Phadia's climate strategy is aligned with the broader goals set by Thermo Fisher Scientific Inc., which has established science-based targets (SBTi) for emissions reductions. However, specific reduction targets or achievements for Phadia itself have not been disclosed. The absence of direct emissions data suggests that Phadia may be in the process of developing its own climate action plan or reporting framework. As part of its corporate family, Phadia is expected to adhere to the sustainability initiatives and performance metrics set by Thermo Fisher Scientific Inc., which include commitments to reduce greenhouse gas emissions across various scopes. This cascading of climate commitments indicates a structured approach to sustainability, although specific details regarding Phadia's individual targets remain unspecified. In summary, while Phadia has not provided concrete emissions data or specific reduction targets, it is positioned within a corporate framework that prioritises climate action and sustainability through its relationship with Thermo Fisher Scientific Inc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 321,190,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 486,151,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Phadia is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
